|
1
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
3
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koturbash I, Zemp FJ, Pogribny I and
Kovalchuk O: Small molecules with big effects: The role of the
microRNAome in cancer and carcinogenesis. Mutat Res. 722:94–105.
2011. View Article : Google Scholar
|
|
5
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
6
|
Eissa S, Ali-Labib R, Swellam M, Bassiony
M, Tash F and El-Zayat TM: Noninvasive diagnosis of bladder cancer
by detection of matrix metalloproteinases (MMP-2 and MMP-9) and
their inhibitor (TIMP-2) in urine. Eururol. 52:1388–1396. 2007.
|
|
7
|
Jiang X, Du L, Wang L, Li J, Liu Y, Zheng
G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression
signatures identified from genome-wide microRNA profiling serve as
novel noninvasive biomarkers for diagnosis and recurrence of
bladder cancer. Int J Cancer. 136:854–862. 2015. View Article : Google Scholar
|
|
8
|
Ratert N, Meyer HA, Jung M, Lioudmer P,
Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert
S, et al: miRNA profiling identifies candidate mirnas for bladder
cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Puerta-Gil P, García-Baquero R, Jia AY,
Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava
F and Sánchez-Carbayo M: miR-143, miR-222, and miR-452 are useful
as tumor stratification and noninvasive diagnostic biomarkers for
bladder cancer. Am J Pathol. 180:1808–1815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang XL, Xie HY, Zhu CD, Zhu XF, Cao GX,
Chen XH and Xu HF: Increased miR-141 expression is associated with
diagnosis and favorable prognosis of patients with bladder cancer.
Tumour Biol. 36:877–883. 2015. View Article : Google Scholar
|
|
11
|
Rouanne M, Loriot Y, Lebret T and Soria
JC: Novel therapeutic targets in advanced urothelial carcinoma.
Crit Rev Oncol Hematol. 98:106–115. 2016. View Article : Google Scholar
|
|
12
|
Iyer G, Al-Ahmadie H, Schultz N, Hanrahan
AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, et
al: Prevalence and co-occurrence of actionable genomic alterations
in high-grade bladder cancer. J Clin Oncol. 31:3133–3140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SL, Cho TM, Won SY, Song JH, Noh DH,
Kim WJ and Moon SK: MicroRNA-20b inhibits the proliferation,
migration and invasion of bladder cancer EJ cells via the targeting
of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol
Rep. 34:1605–1612. 2015.PubMed/NCBI
|
|
14
|
Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS,
Song PH, Choi YH, Kim IY, Moon SK and Kim WJ: Cell-free microRNAs
in urine as diagnostic and prognostic biomarkers of bladder cancer.
Int J Oncol. 41:1871–1878. 2012.PubMed/NCBI
|
|
15
|
Moon SK, Jung SY, Choi YH, Lee YC,
Patterson C and Kim CH: PDTC, metal chelating compound, induces G1
phase cell cycle arrest in vascular smooth muscle cells through
inducing p21Cip1 expression: Involvement of p38 mitogen activated
protein kinase. J Cell Physiol. 198:310–323. 2004. View Article : Google Scholar
|
|
16
|
Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim
JH, Choi YH, Kim WJ and Moon SK: Interleukin-20 promotes migration
of bladder cancer cells through extracellular signal-regulated
kinase (ERK)-mediated MMP-9 protein expression leading to nuclear
factor (NF-χB) activation by inducing the up-regulation of
p21(WAF1) protein expression. J Biol Chem. 288:5539–5552. 2013.
View Article : Google Scholar
|
|
17
|
American Cancer Society: Cancer Facts and
Figures 2015. American Cancer Society; Atlanta, GA: 2015,
http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdfurisimplewww.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
|
|
18
|
Wang F, Zheng Z, Guo J and Ding X:
Correlation and quantitation of microRNA aberrant expression in
tissues and sera from patients with breast tumor. Gynecol Oncol.
119:586–593. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng B, Dong TT, Wang LL, Zhou HM, Zhao
HC, Dong F and Zheng MH: Colorectal cancer migration and invasion
initiated by microRNA-106a. PLoS One. 7:e434522012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C,
Quan L, Bai J and Xu N: miR-106a is frequently upregulated in
gastric cancer and inhibits the extrinsic apoptotic pathway by
targeting FAS. Mol Carcinog. 52:634–646. 2013. View Article : Google Scholar
|
|
21
|
Díaz R, Silva J, García JM, Lorenzo Y,
García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F, et al:
Deregulated expression of miR-106a predicts survival in human colon
cancer patients. Genes Chromosomes Cancer. 47:794–802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Palmer AA, Zhang XD, Thompson JF, Bron LP and Hersey P: Activation
of the extracellular signal regulated kinase (ERK) pathway in human
melanoma. J Clin Pathol. 58:1163–1169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smalley KS: A pivotal role for ERK in the
oncogenic behaviour of malignant melanoma? Int J Cancer.
104:527–532. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yayon A, Ma YS, Safran M, Klagsbrun M and
Halaban R: Suppression of autocrine cell proliferation and
tumorigenesis of human melanoma cells and fibroblast growth factor
transformed fibroblasts by a kinase-deficient FGF receptor 1:
Evidence for the involvement of Src-family kinases. Oncogene.
14:2999–3009. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu GS: Role of mitogen-activated protein
kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev.
26:579–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eissa S, Ahmed MI, Said H, Zaghlool A and
El-Ahmady O: Cell cycle regulators in bladder cancer: Relationship
to schistosomiasis. IUBMB Life. 56:557–564. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shan G and Tang T: Expression of cyclin D1
and cyclin E in urothelial bladder carcinoma detected in tissue
chips using a quantum dot immunofluorescence technique. Oncol Lett.
10:1271–1276. 2015.PubMed/NCBI
|
|
31
|
Zang WQ, Yang X, Wang T, Wang YY, Du YW,
Chen XN, Li M and Zhao GQ: MiR-451 inhibits proliferation of
esophageal carcinoma cell line EC9706 by targeting CDKN2D and
MAP3K1. World J Gastroenterol. 21:5867–5876. 2015.PubMed/NCBI
|
|
32
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao X, Li J, Huang S, Wan X, Luo H and Wu
D: MiRNA-29c regulates cell growth and invasion by targeting CDK6
in bladder cancer. Am J Transl Res. 7:1382–1389. 2015.PubMed/NCBI
|
|
34
|
Liu L, Zhao X, Zhu X, Zhong Z, Xu R, Wang
Z, Cao J and Hou Y: Decreased expression of miR-430 promotes the
development of bladder cancer via the upregulation of CXCR7. Mol
Med Rep. 8:140–146. 2013.PubMed/NCBI
|
|
35
|
Qin H, Sun Y and Benveniste EN: The
transcription factors Sp1, Sp3, and AP-2 are required for
constitutive matrix metalloproteinase-2 gene expression in
astroglioma cells. J Biol Chem. 274:29130–29137. 1999. View Article : Google Scholar : PubMed/NCBI
|
